HEC 53856
Alternative Names: HEC53856; HEC53856 capsuleLatest Information Update: 28 Jun 2022
At a glance
- Originator HEC Pharm
- Developer Sunshine Lake Pharma
- Class Antianaemics
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for phase-I development in Anaemia(In volunteers) in China (PO, Capsule)
- 14 Jun 2021 Sunshine Lake Pharma in collaboration with Nicoya Therapeutics plans a phase I trial for Anemia (in patients with end-stage kidney disease) in China (PO, Capsule) (NCT04925674)
- 14 Jun 2021 Sunshine Lake Pharma in collaboration with Nicoya Therapeutics plans a phase Ib trial for Anaemia in China (PO, Capsule) (NCT04925661)